Large intra- and inter-patient variabilities in absorbed doses delivered during therapies with [177Lu]Lu-SSRT and [177Lu]Lu-PSMA have been demonstrated in several studies, both regarding tumours and normal organs [36, 140]. Here, FOLH1 is linked to neoplasm.